Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (or 40 years or older if you have not had any prior treatment).
- You must have a type of ALL or LBL that has come back after treatment or did not respond to treatment, or you are newly diagnosed and 40 years or older.
- You must be well enough to be up and about at least half the day (ECOG score 0-2).
- Your organs (liver, kidneys, etc.) must be working well enough.
- You cannot have certain types of leukemia (like Ph-positive ALL or Burkitt leukemia/lymphoma).
- You must avoid grapefruit, Seville oranges, and star fruit for 3 days before starting venetoclax, and avoid certain medications that affect the same liver enzyme.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
This trial tests a combination of two targeted drugs (capivasertib and venetoclax) plus a steroid (dexamethasone) in children and young adults with blood cancers that have come back or not responded to treatment. The goal is to see if this drug combination is safe and works against the cancer.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.